Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Lars Anders is active.

Publication


Featured researches published by Lars Anders.


Science | 2014

An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element

Marc R. Mansour; Brian J. Abraham; Lars Anders; Alla Berezovskaya; Alejandro Gutierrez; Adam D. Durbin; Julia Etchin; Lee N. Lawton; Stephen E. Sallan; Lewis B. Silverman; Mignon L. Loh; Stephen P. Hunger; Takaomi Sanda; Richard A. Young; A. Thomas Look

In certain human cancers, the expression of critical oncogenes is driven from large regulatory elements, called super-enhancers, that recruit much of the cell’s transcriptional apparatus and are defined by extensive acetylation of histone H3 lysine 27 (H3K27ac). In a subset of T-cell acute lymphoblastic leukemia (T-ALL) cases, we found that heterozygous somatic mutations are acquired that introduce binding motifs for the MYB transcription factor in a precise noncoding site, which creates a super-enhancer upstream of the TAL1 oncogene. MYB binds to this new site and recruits its H3K27 acetylase–binding partner CBP, as well as core components of a major leukemogenic transcriptional complex that contains RUNX1, GATA-3, and TAL1 itself. Additionally, most endogenous super-enhancers found in T-ALL cells are occupied by MYB and CBP, which suggests a general role for MYB in super-enhancer initiation. Thus, this study identifies a genetic mechanism responsible for the generation of oncogenic super-enhancers in malignant cells. Leukemia-associated mutations drive cell growth by creating a powerful transcriptional enhancer upstream of an oncogene. [Also see Perspective by Vähärautio and Taipale] A super-enhancer in leukemia development Human cancer genome projects have provided a wealth of information about mutations that reside within the coding regions of genes and drive tumor growth by functionally altering protein products. However, this mutational portrait of cancer is incomplete: A growing number of mutations are being found within gene regulatory regions. Mansour et al. present an intriguing example of this in a study of a childhood cancer, T-cell acute lymphoblastic leukemia (see the Perspective by Vähärautio and Taipale). An oncogene known to drive the growth of this cancer is expressed at high levels in the leukemic cells because the cells harbor mutations that create a powerful superenhancer (a DNA sequence that activates transcription) upstream of the oncogene. Science, this issue p. 1373; see also p. 1291


Cancer Cell | 2011

A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer Cells

Lars Anders; Nan Ke; Per Hydbring; Yoon Jong Choi; Hans R. Widlund; Joel M. Chick; Huili Zhai; Marc Vidal; Stephen Gygi; Pascal Braun; Piotr Sicinski

Cyclin D-dependent kinases (CDK4 and CDK6) are positive regulators of cell cycle entry and they are overactive in the majority of human cancers. However, it is currently not completely understood by which cellular mechanisms CDK4/6 promote tumorigenesis, largely due to the limited number of identified substrates. Here we performed a systematic screen for substrates of cyclin D1-CDK4 and cyclin D3-CDK6. We identified the Forkhead Box M1 (FOXM1) transcription factor as a common critical phosphorylation target. CDK4/6 stabilize and activate FOXM1, thereby maintain expression of G1/S phase genes, suppress the levels of reactive oxygen species (ROS), and protect cancer cells from senescence. Melanoma cells, unlike melanocytes, are highly reliant on CDK4/6-mediated senescence suppression, which makes them particularly susceptible to CDK4/6 inhibition.


Diabetes | 2014

Cyclin D1 Represses Gluconeogenesis via Inhibition of the Transcriptional Coactivator PGC1α

Kavita Bhalla; Wan-Ju Liu; Keyata Thompson; Lars Anders; Srikripa Devarakonda; Ruby Dewi; Stephanie Buckley; Bor-Jang Hwang; Brian M. Polster; Susan G. Dorsey; Yezhou Sun; Piotr Sicinski; Geoffrey D. Girnun

Hepatic gluconeogenesis is crucial to maintain normal blood glucose during periods of nutrient deprivation. Gluconeogenesis is controlled at multiple levels by a variety of signal transduction and transcriptional pathways. However, dysregulation of these pathways leads to hyperglycemia and type 2 diabetes. While the effects of various signaling pathways on gluconeogenesis are well established, the downstream signaling events repressing gluconeogenic gene expression are not as well understood. The cell-cycle regulator cyclin D1 is expressed in the liver, despite the liver being a quiescent tissue. The most well-studied function of cyclin D1 is activation of cyclin-dependent kinase 4 (CDK4), promoting progression of the cell cycle. We show here a novel role for cyclin D1 as a regulator of gluconeogenic and oxidative phosphorylation (OxPhos) gene expression. In mice, fasting decreases liver cyclin D1 expression, while refeeding induces cyclin D1 expression. Inhibition of CDK4 enhances the gluconeogenic gene expression, whereas cyclin D1–mediated activation of CDK4 represses the gluconeogenic gene-expression program in vitro and in vivo. Importantly, we show that cyclin D1 represses gluconeogenesis and OxPhos in part via inhibition of peroxisome proliferator–activated receptor γ coactivator-1α (PGC1α) activity in a CDK4-dependent manner. Indeed, we demonstrate that PGC1α is novel cyclin D1/CDK4 substrate. These studies reveal a novel role for cyclin D1 on metabolism via PGC1α and reveal a potential link between cell-cycle regulation and metabolic control of glucose homeostasis.


Journal of Experimental Medicine | 2018

JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia

Marc R. Mansour; Shuning He; Zhaodong Li; Riadh Lobbardi; Brian J. Abraham; Clemens Hug; Sunniyat Rahman; Theresa E. León; You-Yi Kuang; Mark W. Zimmerman; Traci M. Blonquist; Evisa Gjini; Alejandro Gutierrez; Qin Tang; Laura Garcia-Perez; Karin Pike-Overzet; Lars Anders; Alla Berezovskaya; Yi Zhou; Leonard I. Zon; Donna Neuberg; Adele K. Fielding; Frank J. T. Staal; David M. Langenau; Takaomi Sanda; Richard A. Young; A. Thomas Look

A substantial subset of patients with T cell acute lymphoblastic leukemia (T-ALL) develops resistance to steroids and succumbs to their disease. JDP2 encodes a bZIP protein that has been implicated as a T-ALL oncogene from insertional mutagenesis studies in mice, but its role in human T-ALL pathogenesis has remained obscure. Here we show that JDP2 is aberrantly expressed in a subset of T-ALL patients and is associated with poor survival. JDP2 is required for T-ALL cell survival, as its depletion by short hairpin RNA knockdown leads to apoptosis. Mechanistically, JDP2 regulates prosurvival signaling through direct transcriptional regulation of MCL1. Furthermore, JDP2 is one of few oncogenes capable of initiating T-ALL in transgenic zebrafish. Notably, thymocytes from rag2:jdp2 transgenic zebrafish express high levels of mcl1 and demonstrate resistance to steroids in vivo. These studies establish JDP2 as a novel oncogene in high-risk T-ALL and implicate overexpression of MCL1 as a mechanism of steroid resistance in JDP2-overexpressing cells.


Cancer Research | 2016

Abstract 2007: Transcriptional regulatory program controlled by the oncogenic transcription factor LMO1 in neuroblastoma

Takaomi Sanda; Koshi Akahanse; Brian J. Abraham; Nina Weichert; Adam D. Durbin; Lars Anders; Shi Hao Tan; Alice Wei Yee Yam; Lee N. Lawton; Richard A. Young; John M. Maris; A. Thomas Look

Neuroblastoma is an embryonal tumor of the peripheral sympathetic nervous system, accounting for 15% of all childhood cancer deaths. Both overexpression of the transcription factor LMO1 and the polymorphisms within this gene locus are associated with the susceptibility to neuroblastoma, but the oncogenic roles of LMO1 in neuroblastoma pathogenesis have not been elucidated. The roles of LMO1 in T-cell acute lymphoblastic leukemia (T-ALL) are better understood, and these suggest that some of its effects may be similar between the two malignancies. Here we identify the transcriptional regulatory program controlled by LMO1 in neuroblastoma and T-ALL cells. Knockdown of LMO1 induces apoptotic cell death in both tumor types. ChIP-seq and microarray analyses demonstrate that LMO1 frequently co-occupies its target genes with GATA3 and regulates gene expression in a tissue-specific manner. LMO1 positively regulates genes involved in neuronal development, tumor invasion and metastasis in neuroblastoma cells, whereas it regulates genes involved in lymphopoiesis and immune function in T-ALL cells. Gene set enrichment analysis reveals that many genes bound by LMO1 and GATA3 are significantly downregulated upon MYCN knockdown in the MYCN-amplified neuroblastoma cells. Importantly, LMO1 binds at the CDK6 gene locus, which is associated with a super-enhancer both in neuroblastoma and T-ALL cells. The mRNA expression of CDK6 is positively correlated with LMO1 expression in primary neuroblastoma samples. Knockdown of LMO1 downregulates CDK6 protein expression, whereas overexpression of LMO1 upregulates CDK6 expression. CDK6 knockdown induces apoptosis both in neuroblastoma and T-ALL cells. Our results indicate that CDK6 is a critical downstream target that is directly activated by LMO1 and is required for cell survival in neuroblastoma and T-ALL cells. Citation Format: Takaomi Sanda, Koshi Akahanse, Brian J. Abraham, Nina Weichert, Adam Durbin, Lars Anders, Shi Hao Tan, Alice Wei Yee Yam, Lee N. Lawton, Richard A. Young, John M. Maris, A Thomas Look. Transcriptional regulatory program controlled by the oncogenic transcription factor LMO1 in neuroblastoma. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2007.


Cancer Research | 2014

Abstract 3230: Genome-wide localization of anti-cancer drugs

Lars Anders; Matthew G. Guenther; Jun Qi; Zi Peng Fan; Jason J. Marineau; Peter B. Rahl; Jakob Lovén; Alla A. Sigova; William B. Smith; Tong Ihn Lee; James E. Bradner; Richard A. Young

Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA A vast number of small-molecule ligands, including therapeutic drugs under development and in clinical use, elicit their effects by binding specific proteins associated with the genome. An ability to map the direct interactions of a chemical entity with chromatin genome-wide could provide new and important insights into the mechanisms by which such small molecules interfere with tumor cell functions. We have developed a method that couples affinity capture of chemical entities and massively parallel DNA sequencing (Chem-seq) to identify the sites bound by small molecules throughout the human genome. Using Chem-seq, we have uncovered the full repertoire of the genomic sites bound by a BET bromodomain inhibitor, a cyclin-dependent kinase (CDK) inhibitor and a DNA intercalating drug. Moreover, by combining Chem-seq with ChIP-seq, we have characterized the interactions of drugs with their targets throughout the genome of tumor cells. These methods provide a powerful approach to enhance understanding of therapeutic action and characterize the specificity of drugs that interact with DNA or genome-associated proteins. Citation Format: Lars Anders, Matthew G. Guenther, Jun Qi, Zi Peng Fan, Jason J. Marineau, Peter B. Rahl, Jakob Loven, Alla A. Sigova, William B. Smith, Tong Ihn Lee, James E. Bradner, Richard A. Young. Genome-wide localization of anti-cancer drugs. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3230. doi:10.1158/1538-7445.AM2014-3230


Developmental Cell | 2014

D-Cyclins Repress Apoptosis in Hematopoietic Cells by Controlling Death Receptor Fas and Its Ligand FasL

Yoon Jong Choi; Borja Saez; Lars Anders; Per Hydbring; Joanna Stefano; Nickolas A. Bacon; Colleen Cook; Ilona Kalaszczynska; Sabina Signoretti; Richard A. Young; David T. Scadden; Piotr Sicinski


Cancer Cell | 2017

Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers

Per Hydbring; Yinan Wang; Anne Fassl; Xiaoting Li; Veronica Matia; Tobias Otto; Yoon Jong Choi; Katharine E. Sweeney; Jan M. Suski; Hao Yin; Roman L. Bogorad; Shom Goel; Haluk Yuzugullu; Kevin J. Kauffman; Junghoon Yang; Chong Jin; Yingxiang Li; Davide Floris; Richard Swanson; Kimmie Ng; Ewa Sicinska; Lars Anders; Jean Zhao; Kornelia Polyak; Daniel G. Anderson; Cheng Li; Piotr Sicinski


PMC | 2016

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

Shaokun Shu; Charles Y. Lin; Housheng Hansen He; Robert M. Witwicki; Doris P. Tabassum; Justin M. Roberts; Michalina Janiszewska; Sung Jin Huh; Y. Liang; Jeremy Ryan; Ernest Doherty; Hisham Mohammed; Hao Guo; Daniel G. Stover; Muhammad B. Ekram; Guillermo Peluffo; Jonathan D. Brown; Clive D’Santos; Ian E. Krop; Deborah A. Dillon; Michael R. McKeown; Christopher J. Ott; Jun Qi; Min Ni; Prakash Rao; Melissa Duarte; Shwu Yuan Wu; Cheng Ming Chiang; Lars Anders; Richard A. Young


Methods of Molecular Biology | 2016

ChIP- seq Analysis of Human Chronic Myeloid Leukemia Cells

Lars Anders; Zhaodong Li

Collaboration


Dive into the Lars Anders's collaboration.

Top Co-Authors

Avatar

Richard A. Young

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Brian J. Abraham

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Jun Qi

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

James E. Bradner

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Jason J. Marineau

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Matthew G. Guenther

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge